{"disease":{"id":"severe-eosinophilic-asthma","name":"severe eosinophilic asthma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06465485","title":"STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":504,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07214753","title":"A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy","phase":"","overall_status":"RECRUITING","enrollment_count":335,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05180357","title":"RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.","phase":"","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04159519","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03833141","title":"Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.","phase":"","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05440656","title":"A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04680611","title":"Severe Asthma, MepolizumaB and Affect: SAMBA Study","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT07343661","title":"Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":90,"lead_sponsor_name":"Azienda Ospedaliero Universitaria di Cagliari","has_results":false},{"nct_id":"NCT05365841","title":"Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).","phase":"","overall_status":"UNKNOWN","enrollment_count":85,"lead_sponsor_name":"University of Crete","has_results":false},{"nct_id":"NCT04542902","title":"Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Lithuanian University of Health Sciences","has_results":false},{"nct_id":"NCT03907137","title":"Real World Study With Benralizumab in Severe Asthma in Switzerland","phase":"","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04445038","title":"Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT06302959","title":"Clock Proteins as Prognostic Markers","phase":"","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT03739320","title":"A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Sotiria General Hospital","has_results":false},{"nct_id":"NCT06069310","title":"Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National and Kapodistrian University of Athens","has_results":false},{"nct_id":"NCT04126499","title":"Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain","phase":"","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03470311","title":"Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT03652376","title":"Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"University of Rostock","has_results":false},{"nct_id":"NCT05063981","title":"Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Istituti Clinici Scientifici Maugeri SpA","has_results":false},{"nct_id":"NCT05271526","title":"Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)","phase":"","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}